Adams J - Search Results

1

Elliott PJ, Soucy TA, Pien CS, Adams J, Lightcap ES. Elliott PJ, et al. Among authors: adams j. Methods Mol Med. 2003;85:163-72. doi: 10.1385/1-59259-380-1:163. Methods Mol Med. 2003. PMID: 12710207 Review. No abstract available.

2

Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.

Pye J, Ardeshirpour F, McCain A, Bellinger DA, Merricks E, Adams J, Elliott PJ, Pien C, Fischer TH, Baldwin AS Jr, Nichols TC. Pye J, et al. Among authors: adams j. Am J Physiol Heart Circ Physiol. 2003 Mar;284(3):H919-26. doi: 10.1152/ajpheart.00851.2002. Epub 2002 Nov 7. Am J Physiol Heart Circ Physiol. 2003. PMID: 12424098 Free article.

3

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. LeBlanc R, et al. Among authors: adams j. Cancer Res. 2002 Sep 1;62(17):4996-5000. Cancer Res. 2002. PMID: 12208752

4

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL. Orlowski RZ, et al. Among authors: adams j. J Clin Oncol. 2002 Nov 15;20(22):4420-7. doi: 10.1200/JCO.2002.01.133. J Clin Oncol. 2002. PMID: 12431963 Clinical Trial.

5

PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.

Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J, Jiang JD, Muggia FM, Perez-Soler R. Ling YH, et al. Among authors: adams j. Mol Cancer Ther. 2002 Aug;1(10):841-9. Mol Cancer Ther. 2002. PMID: 12492117

6

Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.

Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ. Nawrocki ST, et al. Among authors: adams j. Mol Cancer Ther. 2002 Dec;1(14):1243-53. Mol Cancer Ther. 2002. PMID: 12516957

7

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Papandreou CN, et al. Among authors: adams j. J Clin Oncol. 2004 Jun 1;22(11):2108-21. doi: 10.1200/JCO.2004.02.106. J Clin Oncol. 2004. PMID: 15169797 Clinical Trial.

8

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR. Aghajanian C, et al. Among authors: adams j. Clin Cancer Res. 2002 Aug;8(8):2505-11. Clin Cancer Res. 2002. PMID: 12171876 Clinical Trial.

9

Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R. Ling YH, et al. Among authors: adams j. Clin Cancer Res. 2003 Mar;9(3):1145-54. Clin Cancer Res. 2003. PMID: 12631620

10

Proteasome inhibition: a novel approach to cancer therapy.

Adams J. Adams J. Trends Mol Med. 2002;8(4 Suppl):S49-54. doi: 10.1016/s1471-4914(02)02315-8. Trends Mol Med. 2002. PMID: 11927288 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,821 results

Search Page